Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01712009 · ClinicalTrials.gov registry record · Phase 2
NOLAN: Naproxen or Loratadine and Neulasta
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
NCT01712009 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 600 participants.
The verdict
NCT01712009, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
Study Summary
The primary objective of the study is to estimate the difference in bone pain between breast cancer patients receiving chemotherapy and pegfilgrastim and either no prophylactic intervention, prophylactic naproxen, or prophylactic loratadine.
Interventions
- DRUG Chemotherapy
- BIOLOGICAL Pegfilgrastim
- DRUG Naproxen
- DRUG Loratadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2012-11-01 |
| Est. Completion | 2015-03-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01712009
The ClinicalTrials.gov registry entry for NCT01712009 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Chemotherapy is the first listed.
NCT01712009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01712009 about?
NCT01712009 is a clinical study titled "NOLAN: Naproxen or Loratadine and Neulasta". The primary objective of the study is to estimate the difference in bone pain between breast cancer patients receiving chemotherapy and pegfilgrastim and either no prophylactic intervention, prophylactic naproxen, or prophylactic loratadine.
What is the current status of trial NCT01712009?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2012-11-01. Estimated completion is 2015-03-18.
What interventions are being tested in trial NCT01712009?
The interventions under investigation include: Chemotherapy (DRUG), Pegfilgrastim (BIOLOGICAL), Naproxen (DRUG), Loratadine (DRUG).
Who is sponsoring clinical trial NCT01712009?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.